TPI provides its latest research note on Avacta Group plc (AVCT.L).

Recognising that manufacturing capacity now represents the key challenge it faces in the global provision of its innovative, rapid, saliva-based SARS-CoV-2 antigen test that is being developed with Cytiva (formerly GE Healthcare Life Sciences), Avacta yesterday announced a further production agreement, this time with Abingdon Health (‘Abingdon’).

Claiming Europe’s largest lateral flow test contract manufacturing capacity and capable of delivering millions of units/month, this follows a similar partnership agreement that was put in place with BBI Solutions back on 6 August 2020.

The technology transfer to Abingdon will begin immediately, with the aim of manufacturing an equivalent product which does not require additional clinical validation/regulatory approvals.

Read More

We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to Avacta Group plc Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.

The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

Copyright © 2020 Turner Pope Investments (TPI) Limited, all rights reserved.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned
Share via
Copy link
Malcare WordPress Security